Vitamin B12 deficiency is one of the most common nutritional problems in modern medicine, yet a new consensus from Brazil has delivered a strikingly honest verdict: after more than eight decades of clinical use, doctors still do not know which of the three main replacement routes—oral tablets, sublingual drops or tablets, and intramuscular injections—is actually best for patients. The finding comes from a rigorous Delphi consensus published in eClinicalMedicine, in which twenty Brazilian specialists from haematology, gastroenterology, endocrinology, bariatric surgery, geriatrics, neurology, gynaecology and obstetrics systematically graded the evidence behind every major claim in B12 replacement therapy. Their conclusion, reached with remarkable unanimity, is that all three routes can normalise serum B12 levels, but none has ever been shown in adequately powered randomised trials to outperform the others on the outcomes that genuinely matter to patients: symptom resolution, neurological recovery, functional status and quality of life.
The scale of the knowledge gap is difficult to overstate. Vitamin B12 deficiency affects roughly 6 to 30 percent of older adults, 10 to 30 percent of people with atrophic gastritis, and 5 to 40 percent of patients after bariatric surgery. Its consequences can be devastating and, if treatment is delayed, irreversible: megaloblastic anaemia, peripheral neuropathy, subacute combined degeneration of the spinal cord, cognitive impairment and dementia-like syndromes. Yet the entire evidence base supporting how we replace this vital vitamin rests almost exclusively on a single laboratory number—the serum B12 concentration. No randomised trial of any route has ever measured whether patients actually feel better, whether damaged nerves recover, or whether their daily functioning improves.
To build the consensus, the panel first commissioned a companion systematic review, registered prospectively, that searched PubMed, Embase and Cochrane CENTRAL from inception to July 2025, with an update in July 2026. That review identified just thirteen comparative studies of oral, sublingual and intramuscular replacement in adults, and the evidence they provided was limited, heterogeneous and at variable risk of bias. Most studies compared oral with intramuscular administration and reported broadly comparable short-term biochemical responses. The most quantitative synthesis available, a 2024 network meta-analysis of thirteen studies encompassing 4,275 participants, ranked the intramuscular route highest for biochemical efficacy using SUCRA values—a statistical metric expressing the probability that a treatment ranks among the most effective options—but found no significant difference between the two non-injectable routes. Crucially, the panel emphasised, such biochemical rankings say nothing about clinical benefit.
The consensus process itself followed the RAND/UCLA Appropriateness Method, adapted into a modified two-stage Delphi design. In the first stage, conducted electronically from August 2025, all twenty panellists voted on draft statements using a binary yes-or-no format with pre-defined agreement thresholds: statements required at least 66 percent agreement to pass, with grades rising from D through A to A-plus for unanimous approval. Statements that fell short were revised by an independent facilitator trained in consensus methodology and redistributed. The second stage brought sixteen panellists to São Paulo on October 17, 2025, where remaining statements were debated in person and re-voted anonymously using smartphone-based voting. Two patient representatives with lived experience of B12 deficiency attended as non-voting observers, helping refine the wording of statements and sharpen the focus on outcomes that matter to patients, though they did not cast votes—a limitation the authors openly acknowledge.
The results were notable for their near-total agreement. Of thirty-one graded items, twenty-two—71 percent—reached grade A-plus, meaning one hundred percent of voting panellists agreed, and the remaining nine reached grade A, representing 90 to 99.9 percent agreement. Not a single statement fell below grade A. Twenty-four statements were finalised during the electronic rounds and seven at the in-person meeting. This extraordinary consensus, the authors caution, should not be mistaken for strength of the underlying evidence; rather, it reflects shared recognition among specialists of persistent and clinically relevant gaps in knowledge that have been glossed over for decades.
Among the key statements, the panel unanimously agreed that all three routes can effectively normalise serum B12 in most adults, but that higher oral doses may be needed in patients with atrophic gastritis or malabsorption. In patients without malabsorption, oral therapy appears comparable to injections. For pernicious anaemia—the autoimmune condition in which the stomach loses its ability to produce intrinsic factor, the protein needed to absorb B12—intramuscular administration remains the preferred route, although large oral doses can be efficacious. Perhaps most importantly, the panel agreed with 95 percent agreement that there is insufficient evidence to determine the long-term clinical superiority of any route, and unanimously that route selection should be individualised based on aetiology, patient preference, feasibility and access.
The consensus also exposed deep inconsistencies in how B12 therapy is actually delivered and monitored. Intramuscular regimens vary dramatically in frequency, dose and duration across studies, and no consensus exists on the optimal monitoring interval for serum B12, methylmalonic acid or homocysteine—the functional biomarkers that reflect cellular B12 status more faithfully than serum levels alone. Definitions of treatment response and normalisation vary so widely between studies that comparing them becomes nearly impossible. Maintenance regimens are highly variable and poorly supported by trial data. On safety, the panel found that adverse events are rarely reported and likely underrecognised, that sublingual formulations appear well tolerated but have never undergone systematic safety assessment, and that the discomfort and access requirements of injections could influence adherence, though comparative adherence data remain limited.
Certain patient groups emerged as especially poorly served by the existing evidence. After bariatric surgery, where deficiency rates reach 40 percent, data on sublingual supplementation are sparse, limited to a single small observational study, and while oral B12 may be effective post-operatively, higher doses are probably required. Older adults with cognitive impairment or frailty—a population in which deficiency is both common and potentially contributory to decline—have essentially no outcome-based evidence guiding supplementation. Patients with pernicious anaemia, who depend on lifelong replacement, are strikingly underrepresented in modern trials. The panel also noted that serum B12 alone is an uncertain guide to clinical benefit: levels rise with pharmacological dosing regardless of whether the patient improves, and the magnitude of the rise differs between cyanocobalamin and hydroxocobalamin formulations without implying any clinical advantage.
The disconnect between biochemical success and clinical evidence reflects a broader pattern in medicine, but the stakes here are unusually high because delayed or inadequate treatment can leave patients with permanent neurological damage. Current international guidelines—including those from the American Academy of Family Physicians, the British Society for Haematology, NICE and British Columbia—diverge substantially on route, dosing and monitoring, a variability the authors attribute to weaknesses in the underlying evidence rather than substantive disagreement among experts. Prescribing practices likewise vary widely across clinicians and specialities, often extrapolating from laboratory normalisation to clinical recommendation without any outcome-based trial data to justify the leap.
The consensus panel, funded by the pharmaceutical manufacturer Myralis with safeguards including anonymous voting, a pre-registered evidence base and no funder access to voting data, has set out a prioritised research agenda. Adequately powered, long-term randomised trials comparing all three routes with standardised, patient-centred endpoints—symptom resolution, neurological recovery, functional status and quality of life—should focus first on the highest-need groups: patients after bariatric surgery, older adults with cognitive impairment or frailty, and people with pernicious anaemia. The statements will be submitted to major Brazilian professional societies for endorsement, and the authors call for international validation in other health systems. Until such trials are completed, the practical message for clinicians and patients is clear: any of the three routes can correct the blood test, but choosing between them should rest on the underlying cause of deficiency, patient preference, practical feasibility and access—supported by functional biomarkers and careful clinical assessment rather than blind faith in a serum number.
Subject of Research: Comparative effectiveness of oral, sublingual and intramuscular vitamin B12 replacement routes
Article Title: Vitamin B12 replacement strategies: a Brazilian delphi consensus
Article References: Cohen, R. V., Levinson, R., Baiocchi, O., Salles, J. E. N., Cavalcante França, M., Jr, Navarro, T., Trujilho, F., Soares, J. M., Jr, Nakagawa, D., Valente, M., Barbuti, R., Spera, R. R., Moura, F., Valerio, C., Schiavon, C. A., dos Santos, F. C., Batista Dantas, A. C., Abdo, A., Steiner, M. L., … Bachour, P. (2026). Vitamin B12 replacement strategies: a Brazilian delphi consensus. eClinicalMedicine, 100, Article 104205. https://doi.org/10.1016/j.eclinm.2026.104205
Image Credits: AI Generated
DOI: 10.1016/j.eclinm.2026.104205
Keywords: vitamin B12, cobalamin deficiency, Delphi consensus, intramuscular injection, oral supplementation, sublingual, pernicious anaemia, bariatric surgery, methylmalonic acid, neurological recovery, clinical guidelines, eClinicalMedicine
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 27, 2026). Experts Agree: No Vitamin B12 Route Has Proven Clinical Superiority. Scienmag. https://scienmag.com/experts-agree-no-vitamin-b12-route-has-proven-clinical-superiority/
Ophelia Keating. “Experts Agree: No Vitamin B12 Route Has Proven Clinical Superiority.” Scienmag, 27 September 2026, https://scienmag.com/experts-agree-no-vitamin-b12-route-has-proven-clinical-superiority/. Accessed 27 September 2026.
Ophelia Keating. “Experts Agree: No Vitamin B12 Route Has Proven Clinical Superiority.” Scienmag. September 27, 2026. https://scienmag.com/experts-agree-no-vitamin-b12-route-has-proven-clinical-superiority/
Copy citation Download RIS
Tags: B12 deficiency prevalence in older adultsB12 replacement therapyB12 therapy outcomesbariatric surgeryBrazilian Delphi consensus on B12clinical efficacy of B12 administration routesClinical guidelinescobalamin deficiencyDelphi consensuseClinicalMedicineevidence-based guidelines for B12 deficiencyintramuscular B12 injectionsintramuscular injectionmethylmalonic acidneurological recoveryneurological recovery in B12 deficiencyoral B12 supplementsoral supplementationpernicious anaemiasublingualsublingual B12 dropssymptom resolution in B12 treatmentvitamin B12vitamin B12 deficiency
